More Positive Data For Recordati Cushing's Drug

Isturisa Could Become A Big Earner

 
• By Kevin Grogan

With Isturisa, licensed last year from Novartis, it seems as though the Italian drugmaker has got hold of a therapy that could become lucrative, as well as highly effective for Cushing's disease.

Cushings Syndrome
Cushing’s affects approximately one to two patients per million per year • Source: Shutterstock

More from Rare Diseases

More from Scrip